Objectives: Cytokeratin 19 is significant for indicating cancer cells, and Cyfra 21-1 is a fragment of cytokeratin 19. This retrospective study was designed to define the prognostic value of serum Cyfra 21-1 in epithelial ovarian cancers (EOC). Materials and methods: Serum Cyfra 21-1 concentration was obtained from 42 patients with EOC prior to treatment. Various prognostic aspects were examined using univariable and multivariable analyses. The standard serum marker cancer antigen 125 was measured simultaneously and compared in this analysis. Results: Serum levels of both Cyfra 21-1 and cancer antigen 125 were associated with positive retroperitoneal lymph nodes and platinum resistance; higher levels of Cyfra 21-1 (3.0 ng/mL as the cut-off) were associated with shorter disease-free survival (16 months vs. 28 months, p ¼ 0.001) and overall survival (29 months vs. 41 months, p ¼ 0.007) than lower levels. Further univariable analysis showed that Cyfra 21-1, poor differentiation, and retroperitoneal lymph node metastasis were related to platinum resistance and mortality. Multivariable analysis indicated retroperitoneal lymph node metastasis and serum Cyfra 21-1 were independent risk factors for both disease-free survival and overall survival. Conclusion: The pretreatment level of serum Cyfra 21-1 had remarkable prognostic significance for EOC, indicating poor survival when it was elevated above 3.0 ng/mL.
Introduction
Epithelial ovarian cancer (EOC) is the second most common gynecologic malignancy and most common cause of death among women with gynecologic cancers [1, 2] . The standard treatment for EOC is extensive surgical resection of the primary tumor and all visible tumors in the abdominal cavity, followed by postoperative adjuvant carboplatin and paclitaxel chemotherapy with/without targeted therapy [3e5] . Although adjuvant postoperative chemotherapy with cytotoxic drugs allows nearly all patients with EOC to achieve complete clinical remission, the disease-free interval is short and often transient [6] . Analyses of prognostic factors shows that massive ascites, poor differentiation, lymph node metastases, advanced stage, suboptimal debulking surgery, chemo-resistance, and poor performance status contributes to tumor recurrence and disease-related death. Therefore, preoperative evaluation, using imaging, or serum tumor markers to predict the above-mentioned prognostic factors is important. Defining a serum marker to predict prognosis seems to be a very simple but important method at present to guide the therapeutic plan. Among the serum markers, serum cancer antigen (CA)125 is well known and has been used for long time; it has been considered the "gold standard" for monitoring therapy, indicating optimal surgery and response to chemotherapy [7, 8] . Besides, the specificity of the serum CA125 level seems to be low, because it is elevated in many nonspecific conditions [9e12], including inflammatory disease, endometriosis, benign tumors, menstruation, and cirrhosis of the liver. However, a consensus has not yet been reached in predicting prognosis and survival in EOC [13, 14] . Therefore, many other biomarkers or combinations of these markers have been used to try to identify patients who will benefit from standard treatment; some of them are potential candidates, including HE4 [15] .
Since the 1990s, Cyfra 21-1, a fragment of cytokeratin 19 (CK19), has been introduced as a potential marker for monitoring various kinds of cancers, including breast [16, 17] , liver [18] , lung [19, 20] , thyroid [21] , urinary bladder [22] , esophageal squamous cell carcinoma [23] , colorectal [24] , undifferentiated nasopharyngeal carcinoma [25] , squamous cell carcinoma of the cervix [26] , and ovarian [27, 28] . In the study of nonesmall-cell lung cancer and breast cancer, CK19 was shown to be a better alternative marker than other markers [16, 17, 19, 20] . In addition, CK19 is also an effective and significant marker for detecting circulation cancer cells [29] . Serum CK19 has been reported infrequently in ovarian cancer, with a sensitivity of 33e61.3%, but a specificity of 95%, showing it is not endometriosis-related [30] . Using immunohistochemistry and a monoclonal antibody against CK19 produced in our laboratory [31] , 89% of the ovarian epithelial cancer tissues showed positive (unpublished data). However, the prognostic role of CK19 has not been defined clearly. CK19 was previously recognized as an activator of proteolytic enzymes caspase 3 during cell apoptosis [32] ; however, recent reports showed that CK19 might represent active, proliferative tumor cells, and it was suggested to be a marker for progenitor/stem cells [33, 34] and related to the oncogenesis of cancers [35] . Because CK19 has such potential as an upstream marker for cancer development, it seems worthy of further extensive investigation in various aspects as a tumor marker for ovarian cancer.
To define the prognostic role of serum Cyfra 21-1 in ovarian cancers, especially when compared to the gold standard marker, CA125, we conducted this study aimed at various clinicopathologic factors, response to chemotherapy, and survival.
Patients and methods

Patients and clinicopathologic variables
Serum samples were collected preoperatively from all patients suspected of having ovarian malignancies and sent to the central laboratory of Taipei Veterans General Hospital, Taipei, Taiwan for measurement of a series of tumor markers, including Cyfra 21-1 and CA125. Forty-two patients with EOC confirmed by pathology were included. Staging was based on the International Federation of Gynecology and Obstetrics criteria. Various clinicopathologic factors were recorded, including age, presence of ascites, tumor stage, histological type, differentiation, retroperitoneal lymph node metastasis, the largest diameter of the residual tumor, platinumresistance, and time to recurrence and/or death. The presence of ascites was defined as a finding of >100 mL of intraperitoneal fluid. The standard primary staging surgery consisted of peritoneal washing cytology, total hysterectomy, bilateral adnexectomy, appendectomy, and infracolic omentectomy. Optimal surgery was defined as a tumor with a greatest diameter of <1 cm. Postoperative treatment consisted of six courses of paclitaxel plus carboplatin. Patients were followed-up every 3 months during the first 2 years, then every 6 months thereafter. The median follow-up duration in this study was 31.5 months (range, 1e62 months).
Clinical recurrence was defined by positive findings in the physical examination, imaging, and elevated serum CA125 levels. Platinum-resistance was defined as a clinical recurrence occurring within 6 months after completion of first-line chemotherapy. Disease-free survival (DFS) was measured from the date of the initial laparotomy to the date of recurrence or metastasis. Overall survival (OS) was measured to the date of death or latest follow-up. No patients in this study were lost to follow-up.
Measurement and evaluation of serum Cyfra 21-1 and CA125 levels
Preoperative serum levels of Cyfra 21-1 were determined by a solid-phase "sandwich" immunoradiometric method (CIS Bio International, Gif-sur-Yvette, France) in the radioimmunoassay laboratory of Taipei Veterans General Hospital, following the manufacturer's instructions. The cut-off values were set at 1.9 ng/ mL and 3.0 ng/mL accordingly [17] . The CA125 level was measured by radioimmunoassay at the same laboratory. The cut-off values for CA125 were set at 35 U/mL and 100 U/mL.
Statistical analysis
SPSS version 12.0 (SPSS, Chicago, IL, USA) was used for management of the database and statistical analysis. Comparisons of Table 1 Serum cytokeratin19 fragment (Cyfra 21-1) and cancer antigen (CA125), and the clinicopathologic parameters. the means were performed using the one-way analysis of variance method (one-way ANOVA). It analyses with group as a fixed factor used to assess. The cumulative probability of survival was assessed using the KaplaneMeier method, and survival curves were compared with the log rank test. The univariable analyses of resistance to platinum and outcome were performed with the binary logistic regression method. Multivariable analyses of survival were carried out using the Cox proportional hazards regression model. A p value < 0.05 was considered to be significant.
Results
Correlations between mean serum levels of Cyfra 21-1 and clinicopathologic parameters
The ages of the 42 patients ranged from 19 years to 75 years, with a median of 50 years. The histology included 14 serous-type cancers, six mucinous-type cancers, 13 endometrioid-type cancer, five clear cell-type cancers, and four undifferentiated-type cancers. The mean serum level of preoperative Cyfra 21-1 of the 42 EOC patients was 12.06 ng/mL (range, 0.34e79.38 ng/mL).
The correlations between the mean levels of Cyfra 21-1 and the clinicopathologic parameters are shown in Table 1 . The preoperative serum CA125 levels of 34 of these 42 patients were available for reference. The mean value was 1178.23 U/mL (range, 15e7828 U/ mL). A higher level of CA125 was found in the younger group, although there was no association between Cyfra 21-1 levels and age. The serum levels of both Cyfra 21-1 and CA125 were significantly higher in patients with serous cell type, positive lymph nodes, and resistance to chemotherapy. In addition, Cyfra 21-1 indicated the achievability of optimal surgery, recurrence, and mortality. Neither marker was associated with grades of differentiation.
Correlations between serum Cyfra 21-1 levels and survival
Using the cut-off values of 1.9 ng/mL and 3.0 ng/mL for Cyfra 21-1, the positive rates for EOC were 71.4% (30/42) and 54.8% (23/42), respectively. A preoperative Cyfra 21-1 level > 1.9 ng/mL did not indicate poor survival relative to either DFS or OS ( Table 2) . However, using 3.0 ng/mL as a cut-off value, patients with an elevated Cyfra 21-1 level had significantly shorter DFS (p ¼ 0.001) and OS (p ¼ 0.007) ( Figs. 1 and 2 ). Using 35 IU/mL and 100 IU/mL as cut-off values, the positive rates for CA125 were 88.2% (30/34) and 73.5% (25/34), respectively. Higher CA125 levels had no significantly different effect on either DFS or OS.
Correlations between Cyfra 21-1 and platinum resistance, mortality, and survival
Univariable analysis showed that elevated Cyfra 21-1 levels (3.0 ng/mL), poor differentiation, and retroperitoneal metastasis were significantly associated with platinum resistance and mortality (Table 3 ). Furthermore, multivariable analysis showed that elevated serum Cyfra 21-1 (3.0 ng/mL) was significantly associated with poor DFS (risk ratio ¼ 3.59, 95% CI ¼ 1.02e13.08, p ¼ 0.048) and OS (risk ratio ¼ 3.31, 95% CI ¼ 1.06e10.76, p ¼ 0.040; Table 4 ). However, an elevated serum CA125 level (35 U/mL) was not significant in either univariable or multivariable analysis.
Discussion
Cytokeratins are expressed by all epithelial cells. Expression of cytokeratin is altered during epithelial differentiation, is important for modulation and control of cell-cycle regulation, tumor cell motility, and apoptosis [36] . CK19, a smaller and more acidic type 1 cytokeratin, is expressed in most simple epithelial cells and their malignant counterparts. The CK19 fragment, Cyfra 21-1, with epitope sequences of 311e335 and 346e367, is released into the serum from proliferating cells during the late S and G2 phases [36] . Based on its differential expression in normal and malignant epithelium, Cyfra 21-1 has been evaluated as a hopeful marker for many cancers [37, 38] . Fig. 1 . The KaplaneMeier disease-free survival curves of preoperative serum cyto-keratin19 fragment (Cyfra 21-1) levels divided at 3.0 ng/mL in epithelial ovarian cancer; p ¼ 0.001 using the log rank test. In this study, the mean level of preoperative serum Cyfra 21-1 of the 42 patients with EOC was only 12.06 ng/mL, with a range of 0.34e79.38 ng/mL. This reveals a possible limitation in monitoring disease, because at this level the significance of fluctuated values in low-level positivity would be difficult to determine. By contrast, serum Cyfra 21-1 has demonstrated the advantage of no age difference, so the data might not be confused by the occurrence of many young age-related events, such as vaginal bleeding endometriosis and pelvic inflammatory diseases [39] .
In this prognostic study, Cyfra 21-1 showed consistent effects in many aspects. First of all, the mean serum Cyfra 21-1 levels were significantly higher in the poor prognosis groups, including those with the presence of ascites, retroperitoneal lymph node metastasis, failure of optimal surgery, resistance to chemotherapy, recurrence, and mortality. Second, an elevated serum level of Cyfra 21-1 (>3 ng/mL) was an independent prognostic factor for poor DFS and OS in a multivariable analysis.
However, serum CA125 in this study was not associated with either recurrence or mortality; further adjusting the cut-off levels of CA125 from 35 U/mL to 100 U/mL did not improve the prognostic value. This finding echoes that of other reports, that the initial preoperative serum CA125 level does not reflect survival for EOC patients, although it is still the "gold standard" tool in the monitoring of diseases after treatment. To have survival significance, serum CA125 should be confined to some complex estimations, such as counting half-life, and testing prechemotherapy or at 8 weeks after surgery [7] .
Overcoming resistance to chemotherapy is one of the critical factors for prognosis, and resistance to platinum, especially, is the milestone for successful treatment of women with EOC [40] . In this study, through both univariable and multivariable analyses, we showed that an elevated serum Cyfra 21-1 level was associated with platinum resistance. Gadducci et al [28] had similar findings when using second-look laparotomy for verification of neoplasms. Also, there is some in vitro evidence to suggest that cytokeratins could exert drug resistance. In our previous in vitro study, diminished expression of CK19 in cervical cancer cells after treatment with a monoclonal antibody against CK19 resulted in an increase in cytotoxicity to cisplatin or vinblastine of at least 15fold [41] . Other researchers used cytokeratin transfection and other methods to demonstrate this rarely-noticed mechanism of drug resistance [42] .
In conclusion, the serum Cyfra 21-1 level was significantly correlated with many prognostic factors, including recurrence and survival. It was an independent survival factor as shown in multivariable analysis. The association of Cyfra 21-1 with response to chemotherapy indicates an issue of both academic and clinical interest that may be useful in tailoring chemotherapy in the future. 
